Individuals diagnosed with cancer as adolescents and young adults (AYAs; ages 15–39
years) face unique vulnerabilities. Compared with individuals diagnosed when younger (≤ …

Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy resulting in the
production of abnormal lymphoid precursor cells. Occurring in B-cell and T-cell subtypes …

Adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face
worse outcomes than children. While pediatric-inspired protocols have improved outcomes …

Adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) treated with
asparaginase-containing pediatric regimens are commonly overweight or obese. We …

Cancer outcomes with chemotherapy are inferior in patients of minority racial/ethnic groups
and those with obesity. Chimeric antigen receptor (CAR) T-cell therapy has transformed …

Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory
Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia …

Abstract Background Pegaspargase (PEG‐ASP) is an integral component of therapy for
acute lymphoblastic leukemia (ALL) but is associated with hepatotoxicity that may delay or …

Adolescents and young adults (AYAs; ages 15-39 years) with acute lymphoblastic leukemia
(ALL) have worse outcomes than pediatric patients with ALL. Multiple factors contribute to …

Several international centers have used and reported on pediatric-inspired regimens to treat
adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic …

Asparaginase is a key component of pediatric-inspired regimens in young adults with acute
lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior …